Table 1 Characteristics at baseline by BB intake.
From: Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination
Variable | Category | No BB no. (%) | BB no. (%) | P value |
|---|---|---|---|---|
Total | 863 (90.3) | 93 (9.7) | ||
Age | Median (range) | 60 (30–92) | 63 (48–80) | <0.01 |
<65 | 593 (68.7) | 50 (53.8) | <0.01 | |
⩾65 | 270 (31.3) | 43 (46.2) | ||
BMI | <25 | 459 (59.8) | 48 (53.9) | 0.10 |
25–30 | 238 (31.0) | 27 (30.3) | ||
>30 | 70 (9.1) | 14 (15.7) | ||
T* | 1 | 387 (46.0) | 51 (54.8) | 0.23 |
2 | 340 (40.4) | 31 (33.3) | ||
3 | 42 (5.0) | 4 (4.3) | ||
4 | 72 (8.6) | 7 (7.5) | ||
N* | 0 | 449 (54.4) | 51 (56.0) | 0.89 |
1 | 253 (30.7) | 26 (28.6) | ||
2/3 | 123 (14.9) | 14 (15.4) | ||
Ki-67 | Median (range) | 42 (1–95) | 38 (4–90) | 0.12 |
≤40 | 408 (49.2) | 53 (57.6) | 0.12 | |
>40 | 422 (50.8) | 39 (42.4) | ||
Peritumoural vascular invasion | Absent | 650 (75.8) | 73 (79.3) | 0.39 |
Focal | 110 (12.8) | 11 (12.0) | ||
Extensive | 98 (11.4) | 8 (8.7) | ||
Neoadjuvant chemotherapy | No | 716 (83.0) | 80 (86.0) | 0.45 |
Yes | 147 (17.0) | 13 (14.0) | ||
Type of surgery | MAST | 206 (23.9) | 20 (21.5) | 0.61 |
QUAD | 657 (76.1) | 73 (78.5) | ||
Radiotherapy | No | 138 (16.0) | 12 (12.9) | 0.44 |
Yes | 725 (84.0) | 81 (87.1) | ||
ACEI | No use | 763 (88.4) | 68 (73.1) | <0.01 |
Use | 100 (11.6) | 25 (26.9) | ||
ARB | No use | 817 (94.7) | 80 (86.0) | <0.01 |
Use | 46 (5.3) | 13 (14.0) | ||
CCB | No use | 808 (93.6) | 79 (84.9) | <0.01 |
Use | 55 (6.4) | 14 (15.1) | ||
Diuretic | No use | 785 (91.0) | 60 (64.5) | <0.01 |
Use | 78 (9.0) | 33 (35.5) | ||
Antithrombotics | No use | 837 (97.0) | 83 (89.2) | <0.01 |
Use | 26 (3.0) | 10 (10.8) | ||
Statins | No use | 812 (94.1) | 80 (86.0) | <0.01 |
Use | 51 (5.9) | 13 (14.0) |
